Abpro is a pre-commercial biotechnology company developing multispecific antibody therapeutics in immuno-oncology and ophthalmology. Its two lead candidates are ABP-102 and ABP-201. ABP-102 is a bispecific T-cell engager targeting HER2 and CD3, designed to recruit immune T cells to attack HER2-positive solid tumors such as breast and gastric cancers; the FDA cleared the IND in January 2026, with a Phase 1 trial expected to begin in the first half of 2026. ABP-201 is a dual-targeting antibody inhibiting both VEGF and ANG-2 for wet age-related macular degeneration and diabetic macular edema, with Abpro arguing its four binding sites per molecule could allow less frequent dosing than current standard-of-care therapies. Abpro also has two earlier-stage T-cell engager candidates targeting liver and gastric cancers. Both lead programs are partnered rather than independently commercialized: ABP-102 is partnered with Celltrion, which funds development and commercialization in exchange for a 50/50 profit split and milestone payments; ABP-201 is partially partnered with Abpro Bio for certain geographies. Abpro's drug discovery relies on its DiversImmune platform and its MultiMab engineering platform, which produces its TetraBi antibody format. The company has no approved products, no product revenue, no manufacturing capabilities, and as of early 2026 had only three employees. Abpro was delisted from Nasdaq in February 2026, is in breach of its AstraZeneca license covering ABP-201, and its primary financing facility became unavailable following the delisting.